New treatment for lung cancer shows promise

Nov 15, 2010

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

Lung cancer is the second most common type of cancer in the U.S., accounting for more deaths than breast, prostate and combined, according to the . Many people endure more than one type of lung cancer treatment, which can last for weeks to months.

Lead researcher Raimar Löbenberg and his colleagues Warren Finlay and Wilson Roa from the University of Alberta developed an inhalable dry powder using a common chemotherapy drug encapsulated into nanoparticles. Some mice were treated with the inhalable powder and others with the same drug through two different delivery methods, a solution and IV injection of drug bound nanoparticles.

Results showed that the inhalable dry powder was more effective than using the IV or solution. In the study, more than 80 percent of the mice survived for more than 90 days and more than 70 percent survived for 140 days. None of the mice treated with the IV injection or solution survived past 50 days.

"Current treatments can be grueling and take a significant toll on the patient," said Löbenberg. "Our results show that this treatment method may not only increase someone's survival rate but could also potentially be less toxic to the body."

The inhalable dry powder was also more effective than the IV injection in reducing the amount and size of tumors. Large tumor masses were seen in the lungs of those animals that were not treated or treated with the IV injection or solution. Animals treated with the inhalable dry powder showed fewer and much smaller tumors.

Explore further: Overweight linked to 500,000 cancer cases per year

Provided by American Association of Pharmaceutical Scientists

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New vaccine delivery may be more effective against measles

Sep 28, 2009

Worldwide, there are estimated to be 10 million cases of measles and 197,000 deaths from the disease each year. While vaccines exist to protect children against measles, the vaccines are often difficult to store, costly to ...

Metformin may protect against lung cancer

Sep 01, 2010

Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).

Targeted Nanoparticles Destroy Prostate Tumors

Apr 25, 2006

Biodegradable polymer nanoparticles, linked to a protein-binding nucleic acid known as an aptamer and loaded with the anticancer agent docetaxel, can target and kill prostate tumors growing in mice. Using this targeted nanoparticle ...

Recommended for you

Funding to investigate an alternative to chemotherapy

29 minutes ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

Enzyme may be key to cancer progression in many tumors

32 minutes ago

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.